Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal.

[1]  T. Pajak,et al.  Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal , 1999, Cancer.

[2]  A. Vecchione,et al.  The prevalence of p53 immunoreactivity in anal canal carcinoma. , 1998, Oncology reports.

[3]  H. Adami,et al.  [Sexually transmitted infection as a cause of anal cancer]. , 1997, Ugeskrift for laeger.

[4]  M. Tsao,et al.  Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  H. Bartelink,et al.  Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  I. Talbot,et al.  PROPERTIES OF HPV‐POSITIVE AND HPV‐NEGATIVE ANAL CARCINOMAS , 1996, The Journal of pathology.

[7]  R. James.  Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin , 1996, The Lancet.

[8]  R. Holm,et al.  Anal carcinoma: a clinical approach to p53 and RB gene proteins. , 1996, Oncology.

[9]  N. Petrelli,et al.  Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Bristow,et al.  The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  V. Tron,et al.  Site-specific comparison of p53 immunostaining in squamous cell carcinomas. , 1995, Human pathology.

[12]  S. Syrjänen,et al.  Implications of the p53 tumor-suppressor gene in clinical oncology. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Armand,et al.  High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. , 1995, Oncogene.

[14]  I. Talbot,et al.  Anal carcinoma—a histological review , 1994, Histopathology.

[15]  T. Crook,et al.  Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. , 1994, Oncogene.

[16]  D. Lane,et al.  p53 In tumour pathology: Can we trust immunohistochemistry?—revisited! , 1994, The Journal of pathology.

[17]  B. Vogelstein,et al.  An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms , 1994, The Journal of pathology.

[18]  M. Scheffner,et al.  The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.

[19]  T. Saclarides,et al.  Immunohistochemical detection of mutant P53 protein and human papillomavirus-related E6 protein in anal cancers , 1993, Diseases of the colon and rectum.

[20]  J. Milner,et al.  Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+ p53 conformation. , 1993, Oncogene.

[21]  O. Ogunbiyi,et al.  Immunohistochemical analysis of p53 expression in anal squamous neoplasia. , 1993, Journal of clinical pathology.

[22]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[23]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[24]  V. Vaitkevicius,et al.  Combined therapy for cancer of the anal canal: A preliminary report , 1974, Diseases of the colon and rectum.

[25]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[26]  H. Goldman,et al.  Pathology of the Gastrointestinal Tract , 1992 .

[27]  C. Catton,et al.  Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. , 1991, International journal of radiation oncology, biology, physics.

[28]  T. Crook,et al.  Status of c-myc, p53 and retinoblastoma genes in human papillomavirus positive and negative squamous cell carcinomas of the anus. , 1991, Oncogene.

[29]  M. Hauer-Jensen,et al.  Chemotherapy and radiation therapy for anal carcinoma. Survival and late morbidity , 1991, Cancer.

[30]  M. Hauer-Jensen,et al.  Chemotherapy and Radiation Therapy for Anal Carcinoma , 1991 .

[31]  T. Shows,et al.  Transformation associated p53 protein is encoded by a gene on human chromosome 17 , 1985, Somatic cell and molecular genetics.

[32]  V. Vaitkevicius,et al.  Combined therapy for cancer of the anal canal , 1981, Diseases of the colon and rectum.